Efor Enhances Life Sciences Position with Key Acquisitions of DynamixE and No Deviation

### Efor's Strategic Expansion in Life Sciences Through Key Acquisitions

Efor, a leader in quality and compliance for the Life Sciences industry, makes headlines with two major acquisitions aimed at reinforcing its position in a competitive market. On March 2, 2026, the company announces the acquisition of DynamixE, Inc., a U.S.-based firm known for its expertise in Commissioning, Qualification & Validation (CQV), process engineering, and automation. Established in 2013, Efor currently operates with more than 3,000 employees across 18 nations, generating nearly $60 million in U.S. revenue, part of a global total of approximately $400 million. DynamixE, founded in 2017, specializes in providing CQV solutions and advanced process engineering designed for biologics, cell, and gene therapy biomanufacturing, contributing to Efor's strategic goal of enhancing its operational capabilities in North America.

The acquisition marks a significant step in Efor's growth strategy and represents an expansion of its CQV capabilities within the U.S. market. This joint venture builds upon previous collaborations between Efor and DynamixE, which were essential in completing numerous large-scale projects. According to Mathieu Roger, Efor’s Founder and President, this move significantly accelerates their momentum in establishing a robust presence in quality and compliance. The integrated operations of Efor and DynamixE are expected to yield higher standards of delivery, addressing the intricate demands of the life sciences sector, where a heightened need for quality and compliance services is prevalent.

This development also reflects Efor's broader strategy of pursuing targeted acquisitions to adapt to the rapid changes within the industry. The acquisition signals a commitment not only to expand geographically but also to deepen the company's expertise in critical operational areas tied to biomanufacturing. Kartik Subramanian, Founder and CEO of DynamixE, emphasizes the value of this integration, noting that it would enable both companies to expand their competitive reach while maintaining their dedication to excellence in biomanufacturing processes. By combining their strengths and resources, Efor and DynamixE are poised to respond effectively to the complexities arising within the life sciences sector.

In addition, Efor announces another significant acquisition of Singapore-based No Deviation, establishing a strong foothold in key Asian markets. Founded in 2007, No Deviation has developed robust capabilities in the biopharmaceutical sector across Singapore, China, and Ireland. This acquisition further illustrates Efor's commitment to global expansion and its ambition to enhance its offerings of high-quality compliance solutions tailored for the life sciences industry.

Overall, Efor is on a path to solidifying its leadership position in the global life sciences market, strategically balancing both organic growth and acquisitions that empower its commitment to quality and operational excellence.